I agree that in the penny market we should NOT naively believe what companies trumpet as a general rule...in almost all cases; but EPGL seems to be one of those rare gems of a company that is going to shine and sparkle even more as she is cut and polished by continued extreme performance to reveal what she now hides under a somewhat opaque and rough surface.
Also, 'free float methodology' IS the capitalization method used by the BSE SENSEX30, DOW JONES and S&P, to name a few of the major markets, to value their indexes; but that being said, it stands to reason that each individual company is assigned a value based on the method and that value represents it's true estimate of worth according to the index. You cannot value the whole index by 'free float methodolgy' and then say that if you isolate an individual company you cannot use this method of valuation, but must use the old OS x PPS to arrive at an individual appraisal of company value.
It also stands to reason that what is good for the major indexes as a method is good for the valuation of any company in any market! It is considered to be a newer and more accurate method of valuation and to me it makes sense.
And lastly, I am inclined to believe EPGLs statements regarding how they will handle their large, majority portion of restricted shares. So far they have been nothing but forthright in their interaction with shareholders and stellar in their overall performance as an upstart medical device company. Go EPGL!!!
AI
